Taipei, Dec. 30 (CNA) A new drug targeted at preventing the recurrence of liver cancer after it is treated surgically is expected to receive approval in most Asian countries by 2015, according to the company authorized to develop, produce and market the drug.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Sports
Team Taiwan at the Tokyo Olympics, July 30
07/30/2021 11:15 PM - Sports
Taiwan's Lee, Wang advance to Olympic badminton finals
07/30/2021 11:08 PM - Cross-Strait
Last Taiwanese official in Hong Kong forced home
07/30/2021 10:59 PM - Science & Tech
Taiwan's ex-VP named member of Pontifical Academy of Sciences
07/30/2021 10:36 PM - Sports
Lin Yun-ju's bid for historic table tennis bronze falls just short
07/30/2021 10:15 PM
